Michael R. Zalutsky, Ph.D., is the Jonathan Spicehandler, M.D., Professor of Neuro-Oncology Research and a Professor in the Departments of Radiology, Radiation Oncology, Pathology, and Biomedical Engineering at Duke University. Prior to joining the faculty at Duke, Michael held positions at the Argonne National Laboratory, University of Chicago, and Harvard Medical School. The author of more than 400 scientific publications and patents, his primary research interest is radiochemistry applied to cancer imaging and targeted radionuclide therapy. A major focus of his research has been the development of targeted radiotherapeutics labeled with the alpha particle emitter 211At, including its production, labeling chemistry, radiation dosimetry, and first clinical translation. In addition, his laboratory has been responsible for the development and validation of many of the most widely used methodologies for labeling antibodies and single domain antibody fragments (a.k.a. nanobodies) with radiohalogens including 18F, 131I, and 211At. Dr. Zalutsky’s honors and awards include the Berson-Yalow Award and the Aebersold Award from the Society of Nuclear Medicine for outstanding achievement in basic nuclear medicine science, and a MERIT Award from the National Cancer Institute for his research in targeted alpha-particle radiotherapy.